Ramkrishna Mitra
YOU?
Author Swipe
View article: 15 Augmenting immune checkpoint inhibitor therapy in a head and neck squamous cell carcinoma mouse model using ultrasound-triggered microbubble cavitation
15 Augmenting immune checkpoint inhibitor therapy in a head and neck squamous cell carcinoma mouse model using ultrasound-triggered microbubble cavitation Open
View article: Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC Open
Purpose: Immune checkpoint inhibitors (ICI) have demonstrated clinical benefit in head and neck squamous cell carcinoma (HNSCC); however, single-agent efficacy is limited, leaving significant unmet needs. Metformin may synergize with ICIs,…
View article: TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells
TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells Open
The consequences of activated innate immune signaling in acute myeloid leukemia (AML) is not well understood. Using ligands directed at the toll-like family receptors (TLR) in models of high-risk AML, we uncover that TLR2 ligands exert uni…
View article: Leukotriene B4 regulates T cell recognition and control of MCMV in mucosal tissues
Leukotriene B4 regulates T cell recognition and control of MCMV in mucosal tissues Open
Lipid mediators play important, yet poorly understood roles in regulating immune responses. Cytomegalovirus (CMV) is a herpesvirus that persists in mucosal tissues. Prior work suggests that leukotrienes, a class of inflammatory lipid media…
View article: Immune phenotype in high- versus low-NRF2 high grade serous ovarian cancer and the impact on prognosis
Immune phenotype in high- versus low-NRF2 high grade serous ovarian cancer and the impact on prognosis Open
NRF2 modulates tumor immune microenvironment (IMM) in several cancers. NRF2 is activated in about 50% of high grade serous ovarian cancer (HGSOC), the most aggressive type of ovarian cancer. This study aimed to stratify HGSOC patients’ sam…
View article: Sirt6 deficiency promotes senescence and age-associated intervertebral disc degeneration in mice
Sirt6 deficiency promotes senescence and age-associated intervertebral disc degeneration in mice Open
View article: A model of protein folding with multiple native states: Metamorphicity, Intrinsic disorderness and folding upon binding of proteins
A model of protein folding with multiple native states: Metamorphicity, Intrinsic disorderness and folding upon binding of proteins Open
The sequence-structure-function paradigm in biology states that protein’s amino acid sequence determines its unique folded state structure which in turn dictates its unique biological function. This classic concept has been severely challe…
View article: SIRT6 loss causes intervertebral disc degeneration in mice by promoting senescence and SASP status
SIRT6 loss causes intervertebral disc degeneration in mice by promoting senescence and SASP status Open
Intervertebral disc degeneration is a major risk factor contributing to chronic low back and neck pain. While the etiological factors for disc degeneration vary, age is still one of the most important risk factors. Recent studies have show…
View article: Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma
Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma Open
Prostate cancer has heterogeneous growth patterns, and its prognosis is the poorest when it progresses to a neuroendocrine phenotype. Using bioinformatic analysis, we evaluated RNA expression of neuroendocrine genes in a panel of five diff…
View article: Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma
Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma Open
Clinical trials with single-agent venetoclax/ABT-199 (anti-apoptotic BCL2 inhibitor) revealed that diffuse large B-cell lymphoma (DLBCL) is not solely dependent on BCL2 for survival. Gaining insight into pathways/proteins that increase ven…
View article: Figure S7 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Figure S7 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Evaluation of in vitro ADME properties and in vivo pharmacokinetics of EdC.
View article: Data from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Data from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Anticancer nucleosides are effective against solid tumors and hematologic malignancies, but typically are prone to nucleoside metabolism resistance mechanisms. Using a nucleoside-specific multiplexed high-throughput screening approach, we …
View article: Figure S3 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Figure S3 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Mutation-based sensitivity patterns and correlation analysis of CRISPR knock-out with EdC sensitivity.
View article: Figure S1 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Figure S1 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Sequential steps and intermediates for synthesis of EdC (compound 13).
View article: Figure S2 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Figure S2 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Schematic of semi-unbiased screening approach.
View article: Figure S7 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Figure S7 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Evaluation of in vitro ADME properties and in vivo pharmacokinetics of EdC.
View article: Figure S5 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Figure S5 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
RNA-seq analysis of T-ALL Jurkat and DLBCL SUDHL-10 after 16-hour treatment with 1µM EdC.
View article: Figure S6 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Figure S6 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Additional EdC metabolism data.
View article: Table S3 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Table S3 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
ADME and PK properties of 1µM EdC in vitro.
View article: Figure S8 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Figure S8 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Additional in vivo data.
View article: Table S2 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Table S2 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Data collection and refinement statistics of the dCK/UDP/EdC crystal structure.
View article: Table S2 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Table S2 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Data collection and refinement statistics of the dCK/UDP/EdC crystal structure.
View article: Figure S3 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Figure S3 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Mutation-based sensitivity patterns and correlation analysis of CRISPR knock-out with EdC sensitivity.
View article: Table S4 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Table S4 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Individual blood concentrations (ng/mL) and pharmacokinetic parameters for EdC after IP injection.
View article: Figure S1 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Figure S1 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Sequential steps and intermediates for synthesis of EdC (compound 13).
View article: Supplementary Figure Legends from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Supplementary Figure Legends from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Supplementary Figure Legends
View article: Supplementary Figure Legends from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Supplementary Figure Legends from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Supplementary Figure Legends
View article: Supplementary Methods from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Supplementary Methods from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Additional methods for PRISM screen and EdC synthesis.
View article: Figure S6 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Figure S6 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
Additional EdC metabolism data.
View article: Figure S4 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Figure S4 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress Open
EdC sensitivity correlates with sensitivity to replication stress-inducing compounds.